down arrow

Ensysce Biosciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2936024056
USD
1.63
0.06 (3.82%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.521.68

52 Week

1.4610.96
Valuation
Technical
Day's Volume

CASH

55.99 k

Shareholding (Mar 2025)

FII

10.89%

Held by 4 FIIs

DII

88.29%

Held by 1 DIIs

Promoter

0.00%

How big is Ensysce Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Ensysce Biosciences, Inc. has a market capitalization of 4.93 million, with net sales of 6.22 million and a net profit of -6.82 million over the last four quarters. The company reported shareholder's funds of 3.71 million and total assets of 5.60 million as of Dec 24.

Market Cap: As of Jun 18, Ensysce Biosciences, Inc. has a market capitalization of 4.93 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ensysce Biosciences, Inc. reported net sales of 6.22 million and a net profit of -6.82 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 3.71 million and total assets of 5.60 million.

Read More

What does Ensysce Biosciences, Inc. do?

22-Jun-2025

Ensysce Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $2 million as of March 2025. The company has a market cap of $4.93 million and does not pay dividends.

Overview: <BR>Ensysce Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4.93 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.92 <BR>Return on Equity: -224.12% <BR>Price to Book: 1.62<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Ensysce Biosciences, Inc. overvalued or undervalued?

20-Sep-2025

As of August 16, 2021, Ensysce Biosciences, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 1.85 and significantly negative ROCE and ROE, indicating poor performance compared to peers like ContraFect Corp.

As of 16 August 2021, the valuation grade for Ensysce Biosciences, Inc. moved from expensive to risky, indicating a shift in perception towards the company's financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.85 and negative ratios for EV to EBIT and EV to EBITDA at -0.41. Additionally, the Return on Capital Employed (ROCE) and Return on Equity (ROE) are significantly negative at -685.47% and -224.12%, respectively, which further underscores the company's challenges.<BR><BR>In comparison to its peer, ContraFect Corp., which has a positive EV to EBITDA of 0.1574, Ensysce's negative ratios highlight its underperformance in the industry. The overall valuation suggests that Ensysce is not only struggling financially but also lacks the metrics to justify its current price, reinforcing the notion that it is overvalued. While specific return data is unavailable, the lack of positive returns relative to the S&P 500 may indicate further challenges ahead for the stock.

Read More

Is Ensysce Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of July 29, 2025, Ensysce Biosciences, Inc. shows a mildly bearish trend with mixed signals from indicators, including a mildly bullish MACD and bearish moving averages, suggesting some selling pressure despite longer-term strength.

As of 29 July 2025, the technical trend for Ensysce Biosciences, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages indicate a bearish stance. The Bollinger Bands are bearish on the weekly and mildly bearish on the monthly, while the KST shows a mildly bullish signal on both weekly and monthly time frames. The OBV is mildly bearish on the weekly, indicating some selling pressure. Overall, the mixed signals suggest a mildly bearish outlook with some strength in the longer-term indicators. There is no available return data for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky - Negative EBITDA

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -76.33%, its profits have risen by 41.2%
2

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.53

stock-summary
Return on Equity

-194.46%

stock-summary
Price to Book

1.84

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.88%
0%
-24.88%
6 Months
-29.13%
0%
-29.13%
1 Year
-80.24%
0%
-80.24%
2 Years
-88.07%
0%
-88.07%
3 Years
-24.19%
0%
-24.19%
4 Years
-99.96%
0%
-99.96%
5 Years
-100.0%
0%
-100.0%

Ensysce Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Ensysce Biosciences, Inc. technically bullish or bearish?

As of 29 July 2025, the technical trend for Ensysce Biosciences, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages indicate a bearish stance. The Bollinger Bands are bearish on the weekly and mildly bearish on the monthly, while the KST shows a mildly bullish signal on both weekly and monthly time frames. The OBV is mildly bearish on the weekly, indicating some selling pressure. Overall, the mixed signals suggest a mildly bearish outlook with some strength in the longer-term indicators. There is no available return data for comparison with the S&P 500....

Read More

Is Ensysce Biosciences, Inc. overvalued or undervalued?

As of 16 August 2021, the valuation grade for Ensysce Biosciences, Inc. moved from expensive to risky, indicating a shift in perception towards the company's financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.85 and negative ratios for EV to EBIT and EV to EBITDA at -0.41. Additionally, the Return on Capital Employed (ROCE) and Return on Equity (ROE) are significantly negative at -685.47% and -224.12%, respectively, which further underscores the company's challenges. In comparison to its peer, ContraFect Corp., which has a positive EV to EBITDA of 0.1574, Ensysce's negative ratios highlight its underperformance in the industry. The overall valuation suggests that Ensysce is not only struggling financially but also lacks the metrics to justify its current price, reinforcing the notion that it is overvalued. While specific return dat...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
53.09%
EBIT Growth (5y)
-36.90%
EBIT to Interest (avg)
-8.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
1.41
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.18%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.85
EV to EBIT
-0.41
EV to EBITDA
-0.41
EV to Capital Employed
2.83
EV to Sales
0.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-685.47%
ROE (Latest)
-224.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.82%)

Foreign Institutions

Held by 4 Foreign Institutions (10.89%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 600.00% vs -60.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.00% vs 9.09% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "0.20",
          "chgp": "600.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-2.00",
          "chgp": "10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-2.00",
          "chgp": "15.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,276.40%",
          "val2": "-10,756.20%",
          "chgp": "947.98%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 136.36% vs -12.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 24.53% vs 56.20% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.20",
          "val2": "2.20",
          "chgp": "136.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-10.70",
          "chgp": "37.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "0.40",
          "chgp": "225.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.00",
          "val2": "-10.60",
          "chgp": "24.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,291.80%",
          "val2": "-4,805.20%",
          "chgp": "351.34%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.40
0.20
600.00%
Operating Profit (PBDIT) excl Other Income
-1.80
-2.00
10.00%
Interest
0.00
0.00
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-1.70
-2.00
15.00%
Operating Profit Margin (Excl OI)
-1,276.40%
-10,756.20%
947.98%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 600.00% vs -60.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 15.00% vs 9.09% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
5.20
2.20
136.36%
Operating Profit (PBDIT) excl Other Income
-6.70
-10.70
37.38%
Interest
1.30
0.40
225.00%
Exceptional Items
0.00
0.40
-100.00%
Consolidate Net Profit
-8.00
-10.60
24.53%
Operating Profit Margin (Excl OI)
-1,291.80%
-4,805.20%
351.34%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 136.36% vs -12.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 24.53% vs 56.20% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Ensysce Biosciences, Inc. stock-summary
stock-summary
Ensysce Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."